Local Anesthesia While Awake Versus General Anesthesia for Frozen Shoulder Manipulation
WALANT Technique Versus General Anesthesia in Frozen Shoulder Manipulation: A Prospective Randomized Controlled Trial
1 other identifier
interventional
72
1 country
1
Brief Summary
This study compared two anesthesia approaches for shoulder manipulation in adults with primary frozen shoulder that had not improved after at least 6 months of conservative treatment. A total of 72 participants were randomly assigned to undergo manipulation either with ultrasound-guided wide-awake local anesthesia no tourniquet (WALANT) in an outpatient setting or under general anesthesia in the operating room. The main outcome was shoulder forward flexion 4 weeks after the procedure. Other outcomes included shoulder abduction, external rotation, internal rotation, pain, shoulder function, anxiety before the procedure, and early procedure-related complications. Participants were evaluated before the procedure and during the first 4 weeks after treatment. The study aimed to determine whether outpatient manipulation under WALANT could provide short-term clinical outcomes comparable to those of manipulation under general anesthesia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 15, 2025
CompletedFirst Submitted
Initial submission to the registry
July 23, 2026
CompletedFirst Posted
Study publicly available on registry
July 28, 2026
CompletedJuly 29, 2026
July 1, 2026
6 months
July 23, 2026
July 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean Shoulder Forward Flexion at 4 Weeks
Shoulder forward flexion was measured in degrees using a goniometer. Higher values indicate greater shoulder range of motion. The mean forward flexion value was compared between the two study arms.
4 weeks after the procedure
Secondary Outcomes (10)
Mean Shoulder Abduction
Baseline and 1, 2, 3, and 4 weeks after the procedure
Mean Shoulder External Rotation
Baseline and 1, 2, 3, and 4 weeks after the procedure
Distribution of Shoulder Internal Rotation Categories
Baseline and 1, 2, 3, and 4 weeks after the procedure
Mean Visual Analog Scale Pain Score
Baseline and 1, 2, 3, and 4 weeks after the procedure
Mean Modified UCLA Shoulder Score
Baseline and 1, 2, 3, and 4 weeks after the procedure
- +5 more secondary outcomes
Study Arms (2)
Ultrasound-Guided WALANT-Based Manipulation
EXPERIMENTALParticipants received ultrasound-guided administration of a 25-mL WALANT solution containing 12 mL of 2% lidocaine, 0.5 mL of 1:1,000 epinephrine, 2.5 mL of 8.4% sodium bicarbonate, and 10 mL of 0.9% sodium chloride into the glenohumeral joint, anterior capsule, and coracohumeral ligament region. After a 30-minute waiting period, standardized shoulder manipulation was performed in an outpatient setting.
Manipulation Under General Anesthesia
ACTIVE COMPARATORParticipants underwent standard preoperative preparation and shoulder manipulation in the operating room. General anesthesia was induced with intravenous propofol with mask ventilation provided throughout the procedure. The same standardized shoulder manipulation sequence was used as in the WALANT group.
Interventions
Ultrasound-guided administration of a 25-mL WALANT solution followed by standardized shoulder manipulation after a 30-minute waiting period in an outpatient setting.
Standardized shoulder manipulation performed in the operating room under general anesthesia induced with intravenous propofol.
Eligibility Criteria
You may qualify if:
- Adults aged 18 years or older.
- Diagnosis of primary frozen shoulder.
- Persistent symptoms despite at least 6 months of conservative treatment.
- Frozen shoulder defined by at least one of the following: forward flexion less than 100 degrees, external rotation less than 60 degrees, internal rotation limited such that the dorsum of the hand could not reach above the L5 vertebral level, or at least a 50% reduction in shoulder motion in any plane compared with the unaffected shoulder.
- Willingness to provide written informed consent and comply with the study procedures and follow-up schedule.
You may not qualify if:
- Secondary frozen shoulder.
- Known allergy to any medication planned for use in the study.
- Pregnancy or breastfeeding.
- Severe osteoporosis.
- Unstable systemic medical condition.
- Active infection at the planned intervention site.
- Hemiplegia or hemiparesis affecting the involved extremity.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Izmir Katip Celebi University Ataturk Training and Research Hospital
Izmir, İzmir, 35360, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 23, 2026
First Posted
July 28, 2026
Study Start
February 24, 2025
Primary Completion
August 25, 2025
Study Completion
September 15, 2025
Last Updated
July 29, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Access Criteria
- Data will be available from the corresponding author upon reasonable request. Requests will be evaluated based on the scientific merit of the proposed research and compliance with applicable ethical and patient privacy requirements. Data will be shared only after appropriate institutional approval and completion of a data-use agreement, where required.
De-identified individual participant data underlying the results reported in the publication will be shared.